RESUMEN
Background: In patients with spinal cord injuries (SCIs), infections continue to be a leading cause of morbidity, mortality and hospital admission. Objectives: This study evaluated the long-term impact of a weekly, multidisciplinary Spinal/Antimicrobial Stewardship (AMS) meeting for acute-care SCI inpatients, on antimicrobial prescribing over 3â years. Methods: A retrospective, longitudinal, pre-post comparison of antimicrobial prescribing was conducted at our tertiary hospital in Melbourne. Antimicrobial prescribing was audited in 6â month blocks pre- (25 April 2017 to 24 October 2017), immediately post- (27 March 2018 to 25 September 2018) and 3â years post-implementation (2 March 2021 to 31 August 2021). Antimicrobial orders for patients admitted under the spinal unit at the meeting time were included. Results: The number of SCI patients prescribed an antimicrobial at the time of the weekly meeting decreased by 40% at 3â years post-implementation [incidence rate ratio (IRR) 0.63; 95% CI 0.51-0.79; P ≤ 0.001]. The overall number of antimicrobial orders decreased by over 22% at 3â years post-implementation (IRR 0.78; 95% CI 0.61-1.00; Pâ=â0.052). A shorter antimicrobial order duration in the 3â year post-implementation period was observed (-28%; 95% CI -39% to -15%; P ≤ 0.001). This was most noticeable in IV orders at 3â years (-36%; 95% CI -51% to -16%; Pâ=â0.001), and was also observed for oral orders at 3â years (-25%; 95% CI -38% to -10%; Pâ=â0.003). Antimicrobial course duration (days) decreased for multiple indications: skin and soft tissue infections (-43%; 95% CI -67% to -1%; Pâ=â0.045), pulmonary infections (-45%; 95% CI -67% to -9%; Pâ=â0.022) and urinary infections (-31%; 95% CI -47% to -9%; Pâ=â0.009). Ninety-day mortality rates were not impacted. Conclusions: This study showed that consistent, collaborative meetings between the Spinal and AMS teams can reduce antimicrobial exposure for acute-care SCI patients without adversely impacting 90â day mortality.
RESUMEN
BACKGROUND: Antibiotic allergy labels (AALs), reported by up to 25% of hospitalized patients, are a significant barrier to appropriate prescribing and a focus of antimicrobial stewardship (AMS) programmes. METHODS: A prospective audit of a pharmacist-led AMS penicillin allergy de-labelling ward round at Austin Health (Melbourne, Australia) was evaluated. Eligible inpatients with a documented penicillin allergy receiving an antibiotic were identified via an electronic medical report and then reviewed by a pharmacist-led AMS team. The audit outcomes evaluated were: (i) AMS post-prescription review recommendations; (ii) direct de-labelling; (iii) inpatient oral rechallenge referral; (iv) skin prick testing/intradermal testing referral; and (v) outpatient antibiotic allergy clinic assessment. RESULTS: Across a 5 month period, 106 patients were identified from a real-time electronic prescribing antibiotic allergy report. The highest rate of penicillin allergy de-labelling was demonstrated in patients who were referred for an inpatient oral rechallenge with 95.2% (nâ=â21) successfully having their penicillin AAL removed. From the 22 patients with Type A reactions, 63.6% had their penicillin AAL removed. We demonstrated a significant decrease in the prescribing of restricted antibiotics (defined as third- or fourth-generation cephalosporins, fluoroquinolones, glycopeptides, carbapenems, piperacillin/tazobactam, lincosamides, linezolid or daptomycin) in patients reviewed (pre 42.5% versus post 17.9%, Pâ=â0.0002). CONCLUSIONS: A pharmacist-led AMS penicillin allergy de-labelling ward round reduced penicillin AALs and the prescribing of restricted antibiotics. This model could be implemented at other hospitals with existing AMS programmes.
Asunto(s)
Programas de Optimización del Uso de los Antimicrobianos , Hipersensibilidad a las Drogas/epidemiología , Hipersensibilidad a las Drogas/prevención & control , Etiquetado de Medicamentos , Penicilinas , Farmacéuticos , Antibacterianos/efectos adversos , Australia/epidemiología , Hipersensibilidad a las Drogas/diagnóstico , Humanos , Auditoría Médica , Penicilinas/efectos adversos , Fenotipo , Calidad de la Atención de Salud , Pruebas CutáneasAsunto(s)
Antibacterianos/efectos adversos , Hipersensibilidad a las Drogas/epidemiología , Trasplante de Hígado , Antibacterianos/uso terapéutico , Australia/epidemiología , Cefalosporinas/uso terapéutico , Clostridioides difficile/efectos de los fármacos , Clostridioides difficile/genética , Clostridioides difficile/aislamiento & purificación , Infecciones por Clostridium/tratamiento farmacológico , Infecciones por Clostridium/mortalidad , Farmacorresistencia Bacteriana Múltiple/genética , Femenino , Humanos , Masculino , Nitroimidazoles/uso terapéutico , Penicilinas/uso terapéutico , Estudios Retrospectivos , Combinación Trimetoprim y Sulfametoxazol/uso terapéuticoRESUMEN
The populations of the tunneling states of CH(3) are manipulated by rf irradiation of weakly allowed sideband transitions within the manifold of tunneling-magnetic levels. Substantial positive and negative CH(3) tunneling polarizations are observed, providing a quantum rotor analogue of dynamic nuclear polarization and the solid effect in NMR. The field-cycling NMR technique used in the experiments employs level crossings between tunneling and Zeeman systems to report on the tunneling polarization. The tunneling lifetimes are measured and the field dependence investigated.